Solid lipid nanoparticles: formulation factors affecting cell transfection capacity - PubMed (original) (raw)
. 2007 Jul 18;339(1-2):261-8.
doi: 10.1016/j.ijpharm.2007.03.015. Epub 2007 Mar 12.
Affiliations
- PMID: 17467205
- DOI: 10.1016/j.ijpharm.2007.03.015
Solid lipid nanoparticles: formulation factors affecting cell transfection capacity
A del Pozo-Rodríguez et al. Int J Pharm. 2007.
Abstract
Since solid lipid nanoparticles (SLNs) were introduced as non-viral transfection systems, very few reports of their use for gene delivery have been published. In this work different formulations based on SLN-DNA complexes were formulated in order to evaluate the influence of the formulation components on the "in vitro" transfection capacity. SLNs composed by the solid lipid Precirol ATO 5, the cationic lipid DOTAP and the surfactant Tween 80, and SLN-DNA complexes prepared at different DOTAP/DNA ratios were characterized by studying their size, surface charge, DNA protection capacity, transfection and cell viability in HEK293 cultured cells. The incorporation of Tween 80 allowed for the reduction of the cationic lipid concentration. The formulations prepared at DOTAP/DNA ratios 7/1, 5/1 and 4/1 provided almost the same transfection levels (around 15% transfected cells), without significant differences between them (p>0.05). Other assayed formulations presented lower transfection. Transfection activity was dependent on the DOTAP/DNA ratio since it influences the DNA condensation into the SLNs. DNA condensation is a crucial factor which conditions the transfection capacity of SLNs, because it influences DNA delivery from nanoparticles, gene protection from external agents and DNA topology.
Similar articles
- Solid lipid nanoparticles as potential tools for gene therapy: in vivo protein expression after intravenous administration.
del Pozo-Rodríguez A, Delgado D, Solinís MA, Pedraz JL, Echevarría E, Rodríguez JM, Gascón AR. del Pozo-Rodríguez A, et al. Int J Pharm. 2010 Jan 29;385(1-2):157-62. doi: 10.1016/j.ijpharm.2009.10.020. Epub 2009 Oct 14. Int J Pharm. 2010. PMID: 19835940 - New gene delivery system based on oligochitosan and solid lipid nanoparticles: 'in vitro' and 'in vivo' evaluation.
Delgado D, del Pozo-Rodríguez A, Angeles Solinís M, Bartkowiak A, Rodríguez-Gascón A. Delgado D, et al. Eur J Pharm Sci. 2013 Nov 20;50(3-4):484-91. doi: 10.1016/j.ejps.2013.08.013. Epub 2013 Aug 25. Eur J Pharm Sci. 2013. PMID: 23981333 - Serum-resistant lipopolyplexes for gene delivery to liver tumour cells.
García L, Buñuales M, Düzgüneş N, Tros de Ilarduya C. García L, et al. Eur J Pharm Biopharm. 2007 Aug;67(1):58-66. doi: 10.1016/j.ejpb.2007.01.005. Epub 2007 Jan 23. Eur J Pharm Biopharm. 2007. PMID: 17321729 - Applications of nanoparticle systems in gene delivery and gene therapy.
Kafshdooz T, Kafshdooz L, Akbarzadeh A, Hanifehpour Y, Joo SW. Kafshdooz T, et al. Artif Cells Nanomed Biotechnol. 2016;44(2):581-7. doi: 10.3109/21691401.2014.971805. Epub 2014 Nov 3. Artif Cells Nanomed Biotechnol. 2016. PMID: 25365242 Review. - Lipid-Based DNA Therapeutics: Hallmarks of Non-Viral Gene Delivery.
Buck J, Grossen P, Cullis PR, Huwyler J, Witzigmann D. Buck J, et al. ACS Nano. 2019 Apr 23;13(4):3754-3782. doi: 10.1021/acsnano.8b07858. Epub 2019 Apr 2. ACS Nano. 2019. PMID: 30908008 Review.
Cited by
- Mixed backbone antisense glucosylceramide synthase oligonucleotide (MBO-asGCS) loaded solid lipid nanoparticles: in vitro characterization and reversal of multidrug resistance in NCI/ADR-RES cells.
Siddiqui A, Patwardhan GA, Liu YY, Nazzal S. Siddiqui A, et al. Int J Pharm. 2010 Nov 15;400(1-2):251-9. doi: 10.1016/j.ijpharm.2010.08.044. Epub 2010 Sep 15. Int J Pharm. 2010. PMID: 20816930 Free PMC article. - Use of Protamine in Nanopharmaceuticals-A Review.
Ruseska I, Fresacher K, Petschacher C, Zimmer A. Ruseska I, et al. Nanomaterials (Basel). 2021 Jun 7;11(6):1508. doi: 10.3390/nano11061508. Nanomaterials (Basel). 2021. PMID: 34200384 Free PMC article. Review. - Endocytosis in gene therapy with non-viral vectors.
Perez Ruiz de Garibay A. Perez Ruiz de Garibay A. Wien Med Wochenschr. 2016 May;166(7-8):227-35. doi: 10.1007/s10354-016-0450-5. Epub 2016 May 3. Wien Med Wochenschr. 2016. PMID: 27141862 Review. English. - STAT3 Decoy Oligodeoxynucleotides-Loaded Solid Lipid Nanoparticles Induce Cell Death and Inhibit Invasion in Ovarian Cancer Cells.
Ma Y, Zhang X, Xu X, Shen L, Yao Y, Yang Z, Liu P. Ma Y, et al. PLoS One. 2015 Apr 29;10(4):e0124924. doi: 10.1371/journal.pone.0124924. eCollection 2015. PLoS One. 2015. PMID: 25923701 Free PMC article. - Multicomponent nanoparticles as nonviral vectors for the treatment of Fabry disease by gene therapy.
Ruiz de Garibay AP, Delgado D, Del Pozo-Rodríguez A, Solinís MÁ, Gascón AR. Ruiz de Garibay AP, et al. Drug Des Devel Ther. 2012;6:303-10. doi: 10.2147/DDDT.S36131. Epub 2012 Oct 26. Drug Des Devel Ther. 2012. PMID: 23118528 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources